Myeloproliferative Neoplasms

• EMA approval · 2026-01-13
  EMA Authorised: Inrebic (fedratinib dihydrochloride monohydrate) — Bristol Myers Squibb Pharma EEIG

  The European Medicines Agency authorised Inrebic for myeloproliferative neoplasms, including primary myelofibrosis, with Bristol Myers Squib…

• FDA approval · 2006-08-15
  FDA Approved: HYDROXYUREA — Supplemental Application (Endo USA, Inc.)

  The FDA approved a supplemental application for HYDROXYUREA submitted by Endo USA, Inc.